Various available reports suggest that these PPAR ligands have been able to reduce tumor load and growth and have antiangiogenic and antiproliferative properties, owing to which PPAR could be proven as a potential target to combat lung cancer using different ligands and small molecules that can be designed with an optimized procedure. The gene discussed is PPARA; the disease is lung cancer.